2024/05/08

Received ‘AA’ for the first time in MSCI ESG Ratings

2023/12/15

NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDx ^TM IN JAPAN

2023/10/19

Updated information of sustainability

2023/10/18

Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication

2023/09/25

Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody.